Proof of Concept (Bone Resorption/Bone Mineral Density) Study

This study has been completed.

Sponsor:

Information provided by:

Merck

ClinicalTrials.gov Identifier:

NCT00533650

First received: September 19, 2007

Last updated: September 25, 2007

Last verified: September 2007

Purpose

A study to asses the safety and efficacy of MK0429 in postmenapausal women with osteoporosis.

Condition	Intervention	Phase
Post-Menopausal Osteoporosis	Drug: MK0429	Phase 2

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Treatment

Resource links provided by NLM:

MedlinePlus related topics: Osteoporosis

U.S. FDA Resources

Further study details as provided by Merck:

Study Start Date:	April 2001
Study Completion Date:	April 2001

Eligibility

Criteria

Inclusion Criteria:

Person is a women with osteoporosis who is unwilling or unable to take other treatments for osteoporosis

Exclusion Criteria:

Person has had a previous fracture
Person has rheumatiod arthritis. Person has has certian types of cancer
Person has donated blood or has been in another investigational study within the last 4 weeks

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00533650

Sponsors and Collaborators

Merck

Investigators

Study Director:

Medical Monitor

Merck

More Information

No publications provided

ClinicalTrials.gov Identifier:	NCT00533650 History of Changes
Other Study ID Numbers:	2007_620
Study First Received:	September 19, 2007
Last Updated:	September 25, 2007
Health Authority:	United States: Food and Drug Administration

Additional relevant MeSH terms:

Osteoporosis
Osteoporosis, Postmenopausal
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases

ClinicalTrials.gov processed this record on May 16, 2013